FDA Approval Insights: Ponatinib in Ph+ ALL
Season 1, Episode 18, Apr 08, 06:00 PM
Dr Jabbour expands on the multiple milestones achieved through ponatinib’s FDA approval for patients with Ph-positive ALL; the agent’s potency and unique mechanism of action; and key efficacy and safety data from the PhALLCON trial supporting this regulatory decision.